Recombinant Human Sumo 1 protein is a Human Full Length protein, in the 2 to 97 aa range, expressed in Escherichia coli, with >90% purity and suitable for SDS-PAGE, WB.
S D Q E A K P S T E D L G D K K E G E Y I K L K V I G Q D S S E I H F K V K M T T H L K K L K E S Y C Q R Q G V P M N S L R F L F E G Q R I A D N H T P K E L G M E E E D V I E V Y Q E Q T G G
Application | Reactivity | Dilution info | Notes |
---|---|---|---|
Application SDS-PAGE | Reactivity Reacts | Dilution info - | Notes - |
Application WB | Reactivity Reacts | Dilution info - | Notes - |
Ubiquitin-like protein that can be covalently attached to proteins as a monomer or a lysine-linked polymer. Covalent attachment via an isopeptide bond to its substrates requires prior activation by the E1 complex SAE1-SAE2 and linkage to the E2 enzyme UBE2I, and can be promoted by E3 ligases such as PIAS1-4, RANBP2 or CBX4. This post-translational modification on lysine residues of proteins plays a crucial role in a number of cellular processes such as nuclear transport, DNA replication and repair, mitosis and signal transduction. Involved for instance in targeting RANGAP1 to the nuclear pore complex protein RANBP2. Covalently attached to the voltage-gated potassium channel KCNB1; this modulates the gating characteristics of KCNB1 (PubMed:19223394). Polymeric SUMO1 chains are also susceptible to polyubiquitination which functions as a signal for proteasomal degradation of modified proteins. May also regulate a network of genes involved in palate development. Covalently attached to ZFHX3 (PubMed:24651376).
SMT3C, SMT3H3, UBL1, OK/SW-cl.43, SUMO1, Small ubiquitin-related modifier 1, SUMO-1, GAP-modifying protein 1, SMT3 homolog 3, Sentrin, Ubiquitin-homology domain protein PIC1, Ubiquitin-like protein SMT3C, Ubiquitin-like protein UBL1, GMP1, Smt3C
Recombinant Human Sumo 1 protein is a Human Full Length protein, in the 2 to 97 aa range, expressed in Escherichia coli, with >90% purity and suitable for SDS-PAGE, WB.
pH: 7
Preservative: 1.02% Imidazole
Constituents: 25% Glycerol (glycerin, glycerine), 1.75% Sodium chloride, 0.82% Sodium phosphate, 0.004% (R*,R*)-1,4-Dimercaptobutan-2,3-diol, 0.002% PMSF
Ubiquitin-like protein that can be covalently attached to proteins as a monomer or a lysine-linked polymer. Covalent attachment via an isopeptide bond to its substrates requires prior activation by the E1 complex SAE1-SAE2 and linkage to the E2 enzyme UBE2I, and can be promoted by E3 ligases such as PIAS1-4, RANBP2 or CBX4. This post-translational modification on lysine residues of proteins plays a crucial role in a number of cellular processes such as nuclear transport, DNA replication and repair, mitosis and signal transduction. Involved for instance in targeting RANGAP1 to the nuclear pore complex protein RANBP2. Covalently attached to the voltage-gated potassium channel KCNB1; this modulates the gating characteristics of KCNB1 (PubMed:19223394). Polymeric SUMO1 chains are also susceptible to polyubiquitination which functions as a signal for proteasomal degradation of modified proteins. May also regulate a network of genes involved in palate development. Covalently attached to ZFHX3 (PubMed:24651376).
Belongs to the ubiquitin family. SUMO subfamily.
Cleavage of precursor form by SENP1 or SENP2 is necessary for function.
SUMO 1 also known as small ubiquitin-like modifier 1 is part of the protein family involved in post-translational modification. The protein mechanically adds a SUMO group to target proteins through sumoylation a process similar to ubiquitination. SUMO 1 typically has a molecular mass of around 11 kDa. It expresses in various tissues and cells including the nucleus and cytoplasm of eukaryotic cells. In addition it is important in processes like nuclear transport transcriptional regulation and protein stabilization.
SUMO 1 contributes significantly to maintaining cellular homeostasis. It is an integral part of a SUMOylation complex that modifies other proteins to alter their function localization or interactions. Through its modification actions SUMO 1 affects processes such as DNA repair and the cell cycle. By interacting with components of the nuclear pore complex and transcription factors SUMO 1 modulates essential biological activities at multiple levels within the cell.
This protein plays a significant role in the PI3K/Akt pathway and Wnt signaling. SUMO 1 associates with proteins like RanGAP1 and various transcription factors highlighting the complexity of its regulatory actions. These associations are important for the regulation of cell survival proliferation and differentiation. SUMOylation by SUMO 1 has been linked to an interference with phosphorylation showing its potential influence on cell signaling pathways.
The dysregulation of SUMO 1 is seen in cancer and neurodegenerative diseases. For instance altered SUMOylation patterns contribute to the progression of certain cancers. Furthermore SUMO 1 interacts with proteins like p53 and these interactions can affect tumor suppression and cell cycle regulation. In neurodegenerative disorders disturbed SUMOylation is associated with protein aggregation and neuronal damage implicating SUMO 1 in diseases like Alzheimer's.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
SDS-PAGE analysis of ab140417.
**Blocking buffer:** 5% NFDM/TBST
This data was developed using Anti-Sumo 2 + Sumo 3 + Sumo 4 antibody [EPR7163] ab126606, the same antibody clone in a different buffer formulation.
All lanes: Western blot - Anti-Sumo 2 + Sumo 3 + Sumo 4 antibody [EPR7163] (Anti-Sumo 2 + Sumo 3 + Sumo 4 antibody [EPR7163] ab126606) at 1/5000 dilution
Lane 1: Western blot - Recombinant Human Sumo 1 protein (ab140417) at 0.01 µg
Lane 2: Western blot - Recombinant Human Sumo 2 protein (Recombinant Human Sumo 2 protein ab140420) at 0.01 µg
Lane 3: Recombinant Human Sumo 3 protein (ab140414) at 0.01 µg
Lane 4: Western blot - Recombinant Human Sumo 4 protein (Recombinant Human Sumo 4 protein ab157025) at 0.1 µg
All lanes: Western blot - Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/20000 dilution
Developed using the ECL technique.
Predicted band size: 11 kDa
Observed band size: 16 kDa
Exposure time: 3s
**Blocking buffer:** 5% NFDM/TBST
This data was developed using Anti-Sumo 2 + Sumo 3 + Sumo 4 antibody [EPR300(2)] ab109196, the same antibody clone in a different buffer formulation.
All lanes: Western blot - Anti-Sumo 2 + Sumo 3 + Sumo 4 antibody [EPR300(2)] (Anti-Sumo 2 + Sumo 3 + Sumo 4 antibody [EPR300(2)] ab109196) at 1/200 dilution
Lane 1: Western blot - Recombinant Human Sumo 1 protein (ab140417) at 0.01 µg
Lane 2: Western blot - Recombinant Human Sumo 2 protein (Recombinant Human Sumo 2 protein ab140420) at 0.01 µg
Lane 3: Recombinant Human Sumo 3 protein (ab140414) at 0.01 µg
Lane 4: Western blot - Recombinant Human Sumo 4 protein (Recombinant Human Sumo 4 protein ab157025) at 0.1 µg
All lanes: Western blot - Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/20000 dilution
Developed using the ECL technique.
Predicted band size: 12 kDa
Observed band size: 16 kDa
Exposure time: 20s
**Blocking buffer:** 5% NFDM/TBST
This data was developed using Anti-Sumo 1 antibody [EP298] ab133352, the same antibody clone in a different buffer formulation.
All lanes: Western blot - Anti-Sumo 1 antibody [EP298] (Anti-Sumo 1 antibody [EP298] ab133352) at 1/1000 dilution
Lane 1: Western blot - Recombinant Human Sumo 1 protein (ab140417) at 0.01 µg
Lane 2: Western blot - Recombinant Human Sumo 2 protein (Recombinant Human Sumo 2 protein ab140420) at 0.01 µg
Lane 3: Recombinant Human Sumo 3 protein (ab140414) at 0.01 µg
Lane 4: Western blot - Recombinant Human Sumo 4 protein (Recombinant Human Sumo 4 protein ab157025) at 0.1 µg
All lanes: Western blot - Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/20000 dilution
Developed using the ECL technique.
Predicted band size: 11 kDa
Observed band size: 16 kDa
Exposure time: 10s
**Blocking buffer:** 5% NFDM/TBST
This data was developed using Anti-Sumo 2 + Sumo 3 antibody [EPR4602] ab109005, the same antibody clone in a different buffer formulation.
All lanes: Western blot - Anti-Sumo 2 + Sumo 3 antibody [EPR4602] (Anti-Sumo 2 + Sumo 3 antibody [EPR4602] ab109005) at 1/1000 dilution
Lane 1: Western blot - Recombinant Human Sumo 1 protein (ab140417) at 0.01 µg
Lane 2: Western blot - Recombinant Human Sumo 2 protein (Recombinant Human Sumo 2 protein ab140420) at 0.01 µg
Lane 3: Recombinant Human Sumo 3 protein (ab140414) at 0.01 µg
Lane 4: Western blot - Recombinant Human Sumo 4 protein (Recombinant Human Sumo 4 protein ab157025) at 0.1 µg
All lanes: Western blot - Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/20000 dilution
Developed using the ECL technique.
Predicted band size: 12 kDa
Observed band size: 16 kDa
Exposure time: 20s
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com